🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

16 recruiting trials

for Non Metastatic HER2 Positive Breast Cancer

Real-world Bicohort Observational Study of a Pertuzumab Biosimilar in the Treatment of Breast Cancer: in the Neoadjuvant Setting and in First-line Metastatic Disease NCT07542496n/a2 sites📍 Algiers📍 Algiers Société Algérienne de Formation et Recherche en Oncologie A Study of GB491 in Combination With Letrozole in Patients With HR Positive and HER2 Negative Advanced Breast Cancer NCT05851014Phase 352 sites📍 Bengbu📍 Hefei📍 Hefei Genor Biopharma Co., Ltd. · Tests: GB491 combined with Letrozole, Placebo combined with Letrozole Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1184-01/ PRO1184-001) NCT05579366Phase 1, Phase 266 sites📍 Phoenix📍 Tucson📍 Los Angeles Genmab · Tests: Rina-S, Carboplatin, Bevacizumab, Pembrolizumab, Erythromycin Efficacy of Neoadjuvant Subcutaneous Trastuzumab-Pertuzumab in Algerian Women With Locally Advanced HER2 Positive Breast Cancer NCT07166185n/a1 site📍 Blida Blida 1 University S1703 Serum Tumor Marker Directed Disease Monitoring in Patients With Hormone Receptor Positive Her2 Negative Metastatic Breast Cancer NCT03723928NA723 sites📍 Anchorage📍 Anchorage📍 Anchorage SWOG Cancer Research Network · Tests: Usual care disease monitoring, Serum Tumor Marker directed disease monitoring, Quality-of-Life Assessment, Anxiety Ques… The Prognostic Impact of HER2 Expression in Non-Metastatic HER2-Positive Breast Cancer Treated With Dual HER2-Targeted Therapy NCT07376174n/a1 site📍 Jinan Shandong Cancer Hospital and Institute To Identify Primary Resistance to CDK4/6 Inhibitors in Breast Cancer NCT04660435n/a1 site📍 Prato Fondazione Sandro Pitigliani · Tests: Thymidine kinase activity A Phase 1/2a Study of DB-1303/BNT323 in Advanced/Metastatic Solid Tumors NCT05150691Phase 1, Phase 2102 sites📍 Cerritos📍 Los Angeles📍 San Diego DualityBio Inc. · Tests: DB-1303/BNT323, Pertuzumab Injection, Ritonavir, Itraconazole A Study to Evaluate the Effectiveness and Safety of Inavolisib in Participants With Endocrine-resistant, PIK3CA-mutated, Hormone Receptor-positive, HER2-negative Locally Advanced or Metastatic Breast Cancer NCT07347600n/a32 sites📍 Xiamen📍 Lanzhou📍 Shijiazhuang Hoffmann-La Roche · Tests: Inavolisib, Palbociclib, Fulvestrant Preventing Dato-DXd Associated Stomatitis With Dexamethasone Mouthwash, TROPION-DM NCT06974604Phase 21 site📍 Providence Brown University · Tests: Dexamethasone oral Personalized Neo-Antigen Peptide Vaccine for the Treatment of Stage IIIC-IV Melanoma, Hormone Receptor Positive HER2 Negative Metastatic Refractory Breast Cancer or Stage III-IV Non-Small Cell Lung Cancer NCT05098210Phase 11 site📍 Seattle Fred Hutchinson Cancer Center · Tests: Neoantigen Peptide Vaccine, Nivolumab, Poly ICLC, Echocardiography Test, Multigated Acquisition Scan The Evaluation of PC14586 in Patients With Advanced Solid Tumors Harboring a TP53 Y220C Mutation (PYNNACLE) NCT04585750Phase 1, Phase 276 sites📍 Irvine📍 La Jolla📍 Los Angeles PMV Pharmaceuticals, Inc · Tests: rezatapopt, pembrolizumab GIM27-THERapy: a Study to Describe the Effectiveness of Tucatinib in Combination With Capecitabine and Trastuzumab in the Treatment of Metastatic HER-2 Positive Breast Cancer Patients in Real World Setting NCT07583485n/a30 sites📍 Avellino📍 Ancona📍 Aviano Fondazione Oncotech PROVIDENCE - Prospective Non-interventional Study (NIS) to Examine Patient-reported Outcomes and Real-world Clinical Data in Patients With HER2-positive, HER2-low or HER2-ultralow Unresectable or Metastatic Breast Cancer Treated With Trastuzumab Deruxtecan NCT05573893n/a109 sites📍 Amberg📍 Ansbach📍 Apolda AstraZeneca Imaging Study in Metastatic UC, HR+ and HER2- Breast Cancer, TNBC, and NSCLC NCT07671092EARLY Phase 16 sites📍 St Leonards📍 Nedlands📍 Perth RayzeBio, Inc. · Tests: RYZ211/212 Open-Label Study of BBO-10203 in Subjects With Advanced Solid Tumors NCT06625775Phase 144 sites📍 Duarte📍 Los Angeles📍 San Diego TheRas, Inc., d/b/a BBOT (BridgeBio Oncology Therapeutics) · Tests: BBO-10203, Trastuzumab, Fulvestrant, Ribociclib, FOLFOX
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy